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METHODOLOGY
An ultrasensitive reverse transcription 
polymerase chain reaction assay to detect 
asymptomatic low-density Plasmodium 
falciparum and Plasmodium vivax infections 
in small volume blood samples
Matthew Adams1†, Sudhaunshu N. Joshi1†, Gillian Mbambo1, Amy Z. Mu1, Shay M. Roemmich1, Biraj Shrestha1, 
Kathy A. Strauss1, Nicole Eddington Johnson1, Khine Zaw Oo2, Tin Maung Hlaing2, Zay Yar Han3, 
Kay Thwe Han3, Si Thura4, Adam K. Richards5, Fang Huang1,6, Myaing M. Nyunt1 and Christopher V. Plowe1*†
Abstract 
Background: Highly sensitive, scalable diagnostic methods are needed to guide malaria elimination interventions. 
While traditional microscopy and rapid diagnostic tests (RDTs) are suitable for the diagnosis of symptomatic malaria 
infection, more sensitive tests are needed to screen for low-density, asymptomatic infections that are targeted by 
interventions aiming to eliminate the entire reservoir of malaria infection in humans.
Methods: A reverse transcription polymerase chain reaction (RT- PCR) was developed for multiplexed detection of 
the 18S ribosomal RNA gene and ribosomal RNA of Plasmodium falciparum and Plasmodium vivax. Simulated field 
samples stored for 14 days with sample preservation buffer were used to assess the analytical sensitivity and specific-
ity. Additionally, 1750 field samples from Southeastern Myanmar were tested both by RDT and ultrasensitive RT-PCR.
Results: Limits of detection (LoD) were determined under simulated field conditions. When 0.3 mL blood samples 
were stored for 14 days at 28 °C and 80 % humidity, the LoD was less than 16 parasites/mL for P. falciparum and 19.7 
copies/µL for P. vivax (using a plasmid surrogate), about 10,000-fold lower than RDTs. Of the 1739 samples successfully 
evaluated by both ultrasensitive RT-PCR and RDT, only two were RDT positive while 24 were positive for P. falciparum, 
108 were positive for P. vivax, and 127 were positive for either P. vivax and/or P. falciparum using ultrasensitive RT-PCR.
Conclusions: This ultrasensitive RT-PCR method is a robust, field-tested screening method that is vastly more sensi-
tive than RDTs. Further optimization may result in a truly scalable tool suitable for widespread surveillance of low-level 
asymptomatic P. falciparum and P. vivax parasitaemia.
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Background
Momentum is growing for a campaign to eliminate 
malaria from Southeast Asia in response to the emer-
gence there of multidrug-resistant Plasmodium falcipa-
rum [1]. In pilot studies of a possible elimination strategy, 
high-volume, quantitative polymerase chain reaction 
(qPCR) is being used to identify villages along the Thai-
land-Myanmar border whose inhabitants have a high 
prevalence of sub-microscopic, asymptomatic P. falcipa-
rum infections [2]. These ultrasensitive tests reveal much 
higher prevalences of infection than those detected by 
less sensitive standard microscopy, rapid diagnostic tests 
(RDTs) or polymerase chain reaction (PCR) using Deoxy-
ribonucleic Acid (DNA) extracted from filter paper sam-
ples. The prevalence rates detected by high-volume qPCR 
are being used to select populations for targeted mass 
drug treatment to eliminate malaria. Current methods 
are unscalable however, as they require the collection of 
1–2  mL of venous blood, centrifugation and buffy coat 
removal, and freezing of samples in liquid nitrogen [2] or 
other cold transport [3] to achieve ultrasensitive detec-
tion. Additionally, these methods are genus-specific, and 
do not differentiate between P. falciparum and the other 
common malaria species in Asia, Plasmodium vivax in a 
single test.
Current high-volume qPCR methods target the DNA 
of the P. falciparum multi-copy 18S ribosomal RNA 
(18SrRNA) gene which has five copies in every parasite 
genome (chromosomes 1, 5, 7, 11 and 13), thus lower-
ing the limit of detection about fivefold compared to 
molecular tests targeting single copy genes. However, 
a single asexual parasite circulating in peripheral blood 
has roughly 3500 18SrRNA transcripts [4], providing 
thousands-fold more potential targets in a given blood 
volume. Until now, PCR-based detection methods for 
malaria surveillance typically targeted only DNA because 
ribonucleic acid (RNA) is thought to be too unstable 
to withstand sample storage, transport and processing 
under field conditions.
An improved assay was developed to detect both ribo-
somal RNA and DNA, thus taking advantage of the high 
copy numbers of RNA in small blood volumes, using a 
stabilizing reagent that allows preservation of nucleic 
acids from small volumes of blood suitable for collection 
by finger or ear stick, with minimal sample processing, 
and no cold chain.
Methods
Stabilization, extraction of nucleic acids and reverse 
transcription‑PCR
A 300 µL volume of patient blood was mixed with 750 µL 
of DNA/RNA Shield (Zymo Research, Irvine, CA, USA), 
stored up to 2  weeks at 28  °C or below, then frozen at 
−80 °C until extraction. Total nucleic acid was extracted 
from 200  μL of blood/stabilizer mixture using the 
QIAamp 96 DNA Blood Kit (Qiagen, Valencia, CA, USA) 
following the manufacturer’s instructions, but with an 
elution volume of 50 µL of Buffer AE. RT-PCR was per-
formed with modifications as previously described [5, 6]. 
Specifically, a 10 µL reaction containing 5 µL 2 × Quanti-
tect Multiplex Master Mix, 0.1  µL Quantitect Reverse 
Transcriptase Mix (Qiagen, Valencia, CA, USA), 0.2  µL 
1U/µL heat-labile uracil-DNA glycosolase (Roche Diag-
nostics, Indianapolis, IN, USA), 1.5 µL nucleic acid tem-
plate, RNAse-free water and the primers/probes listed in 
Additional file 1, was used to detect parasite nucleic acid. 
The P. vivax and P. falciparum primers and probes were 
adapted with a modified fluorophore [5] and combined 
with the same internal control primers and probes as the 
recently published described for high-volume qPCR [2]. 
RT-PCR was performed on a Roche Lightcycler 96 or 
480 real time PCR machine (Roche Diagnostics, Indian-
apolis, IN, USA) following the cycling conditions in the 
Additional file  1. Results were analysed with the LC96 
software version 1.1 or the LC480 software 1.5.1. Quan-
titation cycle (Cq) values were determined by the propri-
etary algorithm on the LC96 software and using the ‘fit 
points’ method with the LC480.
Plasmodium falciparum limits of detection under simulated 
field storage conditions
To measure the limits of detection (LoD) for P. falcipa-
rum, mock samples were created to simulate field infec-
tions. Synchronous, ring-state NF54 parasites were 
obtained by a combination of sorbitol synchronization 
and magnetic separation using the QuadroMACS sepa-
rator system with LD columns (Miltenyi Biotec, Auburn, 
CA, USA). Parasites were quantified by microscopy 
then serially diluted in parasite culture media followed 
by a final dilution in malaria-naïve human whole blood, 
resulting in final parasite concentrations of 250,000, 
50,000, 10,000, 2000, 400, 80, 16 and 0 parasites/mL (p/
mL).
Three independent experiments were performed to 
measure the baseline LoD of P. falciparum under ambi-
ent storage conditions (3 days at 22 °C). Each experiment 
followed the standard curve design above and was per-
formed with eight replicates per dilution. The LoD was 
determined using a probit analysis in SAS 9.2 (SAS Insti-
tute, Cary, NC, USA).
The impact of tropical storage conditions after sample 
collection on the P. falciparum LoD was also evaluated. 
The simulated samples, each prepared in quadrupli-
cate, were frozen at −80 °C or stored for three, seven or 
14 days at 28 °C with 80 % relative humidity (RH) prior to 
extraction. LoD was calculated by probit as above.
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Limits of detection in admixtures of Plasmodium 
falciparum and Plasmodium vivax
The LoD for P. falciparum was determined by prepar-
ing and testing three independent sets of P. falciparum 
standard curves as described above, both in the pres-
ence and absence of 3.8 × 104 copies/μL of PUC57 plas-
mid containing a P. vivax 18srRNA gene insert (obtained 
from Gary Fahle, National Institutes of Health Vaccine 
Research Center). Since P. vivax parasites are not sus-
tainable in culture, this plasmid was used as a surrogate 
and reported in copies per μL. It should be noted that 
this plasmid surrogate will not represent the increased 
sensitivity due to RNA present in recently collected para-
sites. The LoD for P. vivax was determined by preparing 
and testing three independent sets of P. vivax plasmid 
standard curves (prepared by making serial 10-fold dilu-
tions of the plasmid) resulting in concentrations ranging 
from 3.8 × 104 to 3.8 × 10−1 copies/μL, both alone and in 
presence of total nucleic acid from 1 × 104 p/mL of NF54 
parasites in blood. Each standard dilution was tested in 
triplicate.
Negative predictive value (NPV), positive predictive 
value (PPV), analytical sensitivity, and analytical speci-
ficity were calculated using SAS 9.2 (SAS Institute, Cary, 
NC, USA) along with the 95 % confidence intervals using 
a two-sided Fisher’s exact test. A McNemar’s test was 
performed using Graphpad. From the probit analysis, a 
LoD was determined in terms of parasites per millilitre 
for P. falciparum or plasmid copies per μL for P. vivax. 
Samples below the determined LoD were not expected to 
be positive, and were omitted from these analyses.
Field test of samples from Southeastern Myanmar
As part of a cross-sectional survey, samples were col-
lected across three townships in Southeastern Myanmar 
following a protocol approved by the Ethics Review Board 
of the Department of Medical Research of the Myanmar 
Ministry of Health. The detailed results of this survey will 
be described in a separate presentation. Blood collected 
by finger stick was used to perform RDTs (Malaria Ag 
P.f/Pv, Standard Diagnostics, Republic of Korea) on site, 
and 0.3 mL of blood was placed into collection tubes as 
described above. Anticoagulated blood was mixed with 
the stabilizer and then transported at ambient tem-
perature to a central laboratory in Yangon for storage at 
−80 °C within 10 days of collection. The frozen samples 
were then shipped to Baltimore where extraction and 
ultrasensitive RT-PCR detection were performed in repli-
cate as described above.
Results
A baseline LoD under ambient storage conditions 
was established by performing three independent 
experiments with eight replicates of each parasite con-
centration per experiment. All 24 replicates of P. falcipa-
rum culture material diluted in uninfected human whole 
blood, ranging from 250,000 to 80 p/mL, were detected 
as positive when stored for 3 days at 22 °C. Of the 24 rep-
licates at 16 p/mL, 18 were detected as positive. The LoD 
under these conditions was determined to be 20.5 p/mL.
The impact of sample storage at higher temperatures 
and RH was evaluated in quadruplicate. All four repli-
cates for each concentration of parasites (250,000 to 80 p/
mL) were detected as positive when samples were imme-
diately frozen at −80  °C or stored for three, seven or 
14 days at 28 °C in 80 % RH before processing. The 16 p/
mL concentration was detected in two of four replicates 
when samples were frozen, as compared to three of four, 
four of four and four of four when samples were stored 
for three, seven or 14 days, respectively. The LoD of P. fal-
ciparum samples when frozen at −80 °C was 23.3 p/mL, 
and when stored for three, seven or 14  days in tropical 
conditions was 20.5, <16 and <16 p/mL, respectively.
To assess the effect of admixtures of P. falciparum 
with P. vivax, nucleic acid from cultured P. falciparum 
parasites diluted in human blood was assessed with and 
without the addition of a P. vivax plasmid surrogate. All 
nine replicates of each P. falciparum concentration from 
250,000 to 80  p/mL were detected in the presence and 
absence of 3.8 × 104 copies/μL of P. vivax plasmid in the 
RT-PCR template. Of the nine replicates of 16  p/mL P. 
falciparum, six were detected when not mixed and three 
were detected when mixed. The resulting LoD of P. fal-
ciparum when mixed with P. vivax was 25.1  p/mL, and 
when not mixed was 21.3 p/mL.
The LoD of P. vivax plasmid with and without added P. 
falciparum (1 × 104 p/mL) and human nucleic acid was 
evaluated. All nine replicates were detected for each plas-
mid concentration, from 5.7 × 104 copies/μL to 5.7 × 102 
copies/μL. In the absence of P. falciparum/human 
nucleic acid, the plasmid was detected nine of nine times 
at 5.7 ×  101 copies/μL, six of nine at 5.7 ×  100 copies/
μL, and two of nine at 5.7 ×  10−1 copies/μL. The plas-
mid, when combined with P. falciparum/human nucleic 
acid, was detected seven of nine times at 5.7 × 101 cop-
ies/μL, zero of nine at 5.7 ×  100 copies/μL, and zero of 
nine at 5.7  ×  10−1 copies/μL. The LoD of the plasmid 
was 19.7 copies/μL. In the presence of ‘contaminating’ P. 
falciparum/human nucleic acid, the LoD of the plasmid 
increased to 49.5 copies/μL.
The LoD for each species as well as the impact of varied 
storage conditions on the LoD are shown in Table 1. Sen-
sitivity, specificity, positive predictive value, and negative 
predictive are shown in Table 2.
The analysis of field samples showed a large proportion 
of infections that were undetectable by RDT. Only two 
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samples were positive for P. falciparum by RDT. Ultrasen-
sitive RT-PCR detected 24 P. falciparum positives and 108 
P. vivax positives with 127 infections being either P. falci-
parum and/or P. vivax. Although the number of positives 
detected by RDT was small, both of the RDT-positive 
infections were also positive by ultrasensitive RT-PCR.
A small fraction of field samples were positive in one 
extracted well but not the other. These samples with 
incongruous results were retested via RT-PCR in quadru-
plicate. Of the two non-replicating P. falciparum positive 
samples, one was detected in all four replicates and the 
other was repeatedly negative. Of the six non-replicating 
P. vivax positive samples, three were repeatedly positive, 
while one was negative. The remaining two samples were 
of mixed results suggesting a very low-density infection 
near the LoD.
Discussion
This assay represents an extremely sensitive, robust and 
potentially scalable procedure for collecting small vol-
ume blood specimens under field conditions to conduct 
molecular surveillance for P. falciparum and P. vivax. 
Building on previous work [2, 5, 6], these improved 
methods for stabilizing nucleic acids before processing 
and detecting both DNA and RNA will permit estima-
tion of malaria prevalence even in hard-to-reach areas far 
from refrigeration or laboratory facilities.
This procedure currently uses 0.3  mL of blood col-
lected from a finger or ear stick. While this volume is 
routinely collected in field studies, to be truly scalable 
the sample volume should be closer to the approximately 
50 μL of finger stick blood typically collected by periph-
eral health care workers for RDTs. A larger volume was 
used to ensure that at least some parasite material would 
be present in the collected blood. However, the nucleic 
acid stabilizer may allow for smaller volumes of blood to 
be collected by disrupting infected red blood cells and 
dispersing thousands of copies of nucleic acid per para-
site throughout the blood/stabilizer mixture. Since only 
approximately 57  μL of blood is used for nucleic acid 
extraction, additional improvements can be made to 
decrease the volume of blood drawn while maintaining 
sensitivity.
Although intrinsically the RT-PCR reporter assay is 
more sensitive than reported, limiting PCR cycles to 
as few as 37 allows for a LoD of 25 parasites/mL while 
Table 1 Limits of  detection of  Plasmodium falciparum under  varied storage conditions of  Plasmodium falciparum 
and Plasmodium vivax admixtures
LoD Limits of detection; Pf P. falciparum; Pv P. vivax; RH relative humidity
a 3.8 × 104 plasmid copies/μL
b 1 × 104 p/mL P. falciparum
Sample collection storage conditions Admixture of P. falciparum and P. vivax
3 days 
at 22 °C
Frozen 
(−80 °C)
3 days at 28 °C 
80 % RH
7 or 14 days at 28 °C 
80 % RH
Pf only Pv only Pf w/Pv plasmida Pv plasmid w/Pfb
Pf LoD (p/mL) 20.5 23.3 20.5 <16 21.3 – 25.1 –
Pv LoD (copies/μL) – – – – – 19.7 – 49.5
Table 2 Sensitivity, specificity, positive predictive value and negative predictive value of the RT-PCR performed on simu-
lated samples
Species test P. falciparum P. vivax
Positive Negative Positive Negative
Species-specific RT-PCR
 Positive 522 0 154 0
 Negative 2 451 2 876
McNemar’s (two‑tailed) test P = 0.4795
Percentage 95 % CI Percentage 95 % CI
 Sensitivity 100 99.30–100 100 97.66–100
 Specificity 99.56 98.41–99.95 99.77 99.18–99.97
 PPV 99.62 98.63–99.95 98.73 95.50–99.85
 NPV 100 99.19–100 100 99.58–100
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minimizing the risk of false positives. As with all highly 
sensitive detection methods, a strict protocol to prevent 
false positives from cross-contamination is required. 
In earlier versions of this assay, each instance of a false 
positive was investigated by root cause analysis which 
identified cross-contamination from adjacent highly par-
asitaemic samples or positive controls. This contamina-
tion was subsequently minimized by adhering to a strict 
protocol including the use of mechanical barriers during 
extraction and RT-PCR setup, using several negative con-
trols, and limiting the number of cycles used for analysis.
Conclusion
Ongoing malaria surveys using 0.3 mL samples in Myan-
mar and China will provide estimates of the prevalence 
of P. falciparum and P. vivax infection across a range of 
epidemiological settings. While the current assay will not 
provide a precise quantitation of parasites/mL in these 
field samples, it is possible to infer the relative prevalence 
of very low parasitaemia infections based on the RT-PCR 
threshold cycle. In other words, with clinical malaria rep-
resenting the ‘tip of the iceberg’, use of an ultra-sensitive 
detection method will reveal the shape of the submerged 
iceberg, i.e., the distribution of sub-patent infections with 
relatively high, medium and low parasite densities. If very 
low density infections, those near the current LoD of the 
assay, represent only a small fraction of the asymptomatic 
reservoir of infection, then a compromise allowing for 
both a decrease in the volume of blood collected and an 
increase in the threshold for a positive test result, will fur-
ther improve scalability and reduce the risk of false positive 
tests. If these refinements based on field testing are suc-
cessful, and especially if ongoing efforts to achieve similar 
low LoDs using dried blood spots succeed, this ultrasensi-
tive multiplexed malaria test has the potential to become 
part of a minimum standard toolkit for surveillance for 
malaria elimination campaigns in the Greater Mekong 
Subregion and elsewhere. Anticipating these improve-
ments of the assay, capacity is being established for high 
throughput molecular surveillance for P. falciparum and P. 
vivax malaria in civilian and military laboratories in Myan-
mar, and technical support is available for malaria surveil-
lance laboratories to perform this test worldwide.
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